Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 5 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Xizang Haisco Pharmaceutical Co., Ltd. has 7 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 7 distinct examiners across 5 distinct art units, indicating broad distribution among technical examination groups. The record does not show concentration of pending work with a single examiner.
PECKHAM, RICHARD GRANT is the busiest examiner, with 1 pending matter. Counsel should use portfolio-level docket controls to monitor separate response positions, while comparing the matters for recurring prior-art, written-description, or enablement themes. Consistent scientific terminology may improve coherence, but the broad assignments favor individualized prosecution analysis.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (14%) |
| §102 only | 1 (14%) |
| Double-patenting + other | 1 (14%) |
| Multi-statute (no §101) | 4 (57%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PECKHAM, RICHARD GRANT | 1 | 68.1% | +36.1% |
| LEE, CHIHYI NMN | 1 | 33.3% | +61.1% |
| YOUNGBLOOD, WILLIAM JUSTIN | 1 | 60.0% | +41.6% |
| CLARK, AMY LYNN | 1 | 39.2% | +31.1% |
| INAM, SAHAR | 1 | 100.0% | +0.0% |
| RODRIGUEZ-GARCIA, VALERIE | 1 | 68.9% | +31.7% |
| YOO, SUN JAE | 1 | 71.2% | +0.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18836350 | PREPARATION METHOD OF PYRIDAZINONE DERIVATIVE, AND INTERMEDIATE THEREOF | PECKHAM, RICHARD GRANT | — |
| 18703432 | PARP-1 DEGRADATION AGENT AND USE THEREOF | YOUNGBLOOD, WILLIAM JUSTIN | — |
| 18697424 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE PARP INHIBITOR AND USE THEREOF | CLARK, AMY LYNN | — |
| 18688647 | COMPOUND FOR DEGRADATION OF BCL-2 FAMILY PROTEINS AND MEDICAL APPLICATION THEREOF | INAM, SAHAR | — |
| 18579733 | AAK1 INHIBITOR AND USE THEREOF | RODRIGUEZ-GARCIA, VALERIE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18836350 | PREPARATION METHOD OF PYRIDAZINONE DERIVATIVE, AND INTERMEDIATE THEREOF | PECKHAM, RICHARD GRANT | — |
| 18725087 | PROPIONIC ACID DERIVATIVE AND MEDICAL USE THEREOF | LEE, CHIHYI NMN | — |
| 18703432 | PARP-1 DEGRADATION AGENT AND USE THEREOF | YOUNGBLOOD, WILLIAM JUSTIN | — |
| 18697424 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE PARP INHIBITOR AND USE THEREOF | CLARK, AMY LYNN | — |
| 18579733 | AAK1 INHIBITOR AND USE THEREOF | RODRIGUEZ-GARCIA, VALERIE | — |
| Art Unit | Apps |
|---|---|
| 1628 | 2 |
| 1621 | 2 |
| 1627 | 1 |
| 1629 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18836350 | PREPARATION METHOD OF PYRIDAZINONE DERIVATIVE, AND INTERMEDIATE THEREOF | PECKHAM, RICHARD GRANT | 1627 | §103§112 | Non-Final OA | — | Pending | Aug 06, 2024 |
| 18725087 | PROPIONIC ACID DERIVATIVE AND MEDICAL USE THEREOF | LEE, CHIHYI NMN | 1628 | §103§112DP | Non-Final OA | — | Pending | Jun 27, 2024 |
| 18703432 | PARP-1 DEGRADATION AGENT AND USE THEREOF | YOUNGBLOOD, WILLIAM JUSTIN | 1629 | §101§112 | Non-Final OA | — | Pending | Apr 22, 2024 |
| 18697424 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE PARP INHIBITOR AND USE THEREOF | CLARK, AMY LYNN | 1628 | §103§112Other | Non-Final OA | — | Pending | Mar 29, 2024 |
| 18688647 | COMPOUND FOR DEGRADATION OF BCL-2 FAMILY PROTEINS AND MEDICAL APPLICATION THEREOF | INAM, SAHAR | 1622 | §102§103 | Non-Final OA | — | Pending | Mar 01, 2024 |
| 18579733 | AAK1 INHIBITOR AND USE THEREOF | RODRIGUEZ-GARCIA, VALERIE | 1621 | §102§103§112 | Final Rejection | — | Pending | Jan 16, 2024 |
| 18015309 | PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | YOO, SUN JAE | 1621 | §102 | Final Rejection | 39d | Pending | Jan 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialXizang Haisco Pharmaceutical Co., Ltd. has 7 pending office actions as of October 2026, spread across 5 art units and 7 examiners.
Richard Grant Peckham has the most, with 1 of Xizang Haisco Pharmaceutical Co., Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
